600% Kurspotential YM Biosciences 911799
Seite 25 von 28 Neuester Beitrag: 19.02.13 20:54 | ||||
| Eröffnet am: | 14.03.06 11:16 | von: qwertz | Anzahl Beiträge: | 694 |
| Neuester Beitrag: | 19.02.13 20:54 | von: der Eibsche | Leser gesamt: | 133.249 |
| Forum: | Hot-Stocks | Leser heute: | 3 | |
| Bewertet mit: |  | |||
| Seite: < 1 | ... | 22 | 23 | 24 | | 26 | 27 | 28 > | ||||
TSX:YM), today announced it will present preclinical results for its CYT387
JAK1/JAK2 inhibitor program demonstrating that CYT387 possesses an excellent
enzymatic potency and selectivity profile which may provide significant
clinical advantages.
CYT387 is currently being investigated in a Phase I/II
clinical study at Mayo Clinic in patients with myelofibrosis. The results will
be presented in a poster session at the European School of Haematology
International (ESH) International Conference on Myeloproliferative Neoplasms
in Albufeira, Portugal held from September 30-October 2, 2010.
http://www.cnxmarketlink.com/en/releases/archive/...010/01/c7065.html
(NYSE Amex:YMI, TSX:YM), today announced it has appointed Dr. Nick Glover as Chief Executive Officer of the Company to be effective at the Company's Annual General Meeting on November 18, 2010. Dr. Glover will also be nominated as a Director of the Company at that time. Mr. David Allan, who has been Chairman of the Company since its founding in 1994 and CEO since 1998, will continue to serve as Chairman of YM's Board of Directors.
"Given the rapid progress being made with our recently acquired CYT387 JAK inhibitor program, the ongoing advancement of nimotuzumab globally, and the compelling prospects for the vascular disrupting agent CYT997, this is the ideal time to strengthen our team with strong leadership to advance these programs energetically," said David Allan, Chairman and CEO of YM BioSciences. "In addition to his professional and academic qualifications, Nick has served as COO and President for the last several months and has demonstrated to the Board that he is an exceptional candidate with the right experience and skills to lead YM.
I look forward to working with Nick through this transition in my role as Chairman and will continue to support YM's relationships with the investment community." "David is a pioneer in our industry, having built YM BioSciences since its inception into a strong and vibrant company with a portfolio of promising late-stage products supported by a healthy balance sheet," said Dr. Nick Glover, President and COO of YM BioSciences. "David's approach of focusing primarily on drug development and his strategies for reducing risk via a diversified portfolio model and licensing philosophy were uncommon at the time of the Company's founding and have since been adopted by many companies. We are grateful for David's vision and astute leadership and welcome the ongoing guidance he will provide." Dr. Glover joined YM in June 2010 and is currently serving as President and COO.
He was formerly the President and Chief Executive Officer at Viventia Biotech Inc., a biopharmaceutical company involved in the discovery and development of monoclonal antibody-based technologies for the treatment of cancer. In addition to his operational experience, Dr. Glover has a background in business development and prior to joining Viventia was an investment manager for a leading venture capital firm. Dr. Glover holds a B.Sc. (Hons) in Chemistry from the University of East Anglia, U.K., a M.Sc. in Chemistry from the University of British Columbia, Canada, and a Ph.D. in Chemistry from Simon Fraser University, Canada.
Annual Meeting YM BioSciences' Annual Meeting of Shareholders will be held on November 18, 2010 at 4:00 p.m. ET at the offices of Ogilvy Renault, 200 Bay Street, Suite 3800, Toronto, Ontario. The management proxy circular documents and annual financial documents will be mailed to shareholders on October 15th, 2010 and are available online at www.ymbiosciences.com, www.edgar.com and www.sedar.com.
About YM BioSciences YM BioSciences Inc. is a drug development company advancing three clinical-stage products: CYT387, a small molecule, dual inhibitor of JAK1/JAK2 kinase; nimotuzumab, an EGFR-targeting monoclonal antibody; and CYT997, a potent vascular disrupting agent (VDA).
CYT387 is an orally administered inhibitor of both the JAK1 and JAK2 kinase enzymes, which have been implicated in a number of immune cell disorders including myeloproliferative disorders and inflammatory diseases as well as certain cancers. CYT387 is currently in a Phase II trial in myelofibrosis with detailed initial safety and activity data expected at the American Society of Hematology (ASH) meeting in December 2010. Nimotuzumab is a humanized monoclonal antibody targeting EGFR with a potential best-in-class side effect profile.
Nimotuzumab is being evaluated in numerous Phase II and III trials worldwide by YM's licensees. CYT997 is a uniquely orally-available agent with dual mechanisms of vascular disruption and cytotoxicity, and is currently in a Phase II trial for glioblastoma multiforme. In addition to YM's three clinical stage products, the Company has a library of more than 4,000 novel compounds identified through internal research conducted at YM BioSciences Australia (formerly Cytopia) which are currently being evaluated.
This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that our JAK1/JAK2 inhibitor CYT387 and our VDA small molecule CYT997 will generate positive efficacy and safety data in future clinical trials; that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. Except as required by applicable securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE YM BioSciences Inc.
www.prnewswire.com Copyright (C) 2010 PR Newswire. All rights reserved -0- KEYWORD: Ontario INDUSTRY KEYWORD: MTC
BIO SUBJECT CODE: PER
More News related to YMI
Rodman & Renshaw Initiates Coverage on YM BioSciences (YMI) with a Market Outperform
YM Biosciences (YMI) Appoints Nick Glover as CEO
YM BioSciences (YMI) Names Dr. Nick Glover as CEO
YM BIOSCIENCES APPOINTS DR. NICK GLOVER AS CHIEF EXECUTIVE OFFICER AND ANNOUNCES ANNUAL MEETING
YM Biosciences To Present Poster On CYT387 At The European School Of Haematology International Conference
More News related to YMI
More News related to New Coverage
Barclays on U.S. Display & Lighting: LED - Pockets of Differentiation in a Commoditized World; Initiates Coverage for AIXG, CREE & VECO
Traders Cheer Sidoti's New Buy Rating on Kelly Services (KELYA); Stock Up 2.4% Today
Credit Suisse Starts Coverage on 15 Stocks in the Casino and Lodging Sectors
Feltl Initiates Coverage on Electromed (ELMD) With a Buy
Longbow Initiates Oiln (OLN) at Neutral
More News related to New Coverage
October 19, 2010 9:17 AM EDT
Rodman & Renshaw initiates coverage on YM BioSciences (NYSE Amex: YMI) with a Market Outperform rating. PT $4.
Results to be presented at the 52nd American Society of Hematology Annual Meeting
YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), today announced that data from the initial portion of the Phase I/II trial of its JAK1/JAK2 Inhibitor, CYT387, will be reported in an oral presentation at the 52nd American Society of Hematology (ASH) Annual Meeting to be held in Orlando, Florida on December 4-7th, 2010. The presentation is entitled: "A Phase I/II Study of CYT387, an oral JAK-1/2 inhibitor, in Myelofibrosis: Significant Response Rates in Anemia, Splenomegaly, and Constitutional Symptoms". The abstract describing these results was published online today by ASH and is also available at YM BioSciences' website (www.ymbiosciences.com).
"In addition to demonstrating substantial activity in reducing spleen size and controlling constitutional symptoms, CYT387 also improved anemia in a considerable number of patients. This additional benefit could significantly differentiate our JAK1/JAK2 inhibitor from others in development, which have reported limited anemia benefit or worsened anemia in some patients," said Dr. Nick Glover, President and COO of YM BioSciences. "We look forward to the presentation of detailed results from this first group of patients at ASH and anticipate that data from the full Phase II portion of the study will be available in mid-2011."
http://www.ymbiosciences.com/investors/...ses_item.php?newsid=1493317
BRIEF-RESEARCH ALERT-Versant raises YM BioSciences price target
Nov 10 (Reuters) - YM BioSciences Inc:
* Versant partners raises YM BioSciences Inc price target to C$4 from
C$2.75; rating buy
For a summary of rating and price target changes on S&P 500 companies:
Reuters 3000Xtra users, double-click
Reuters Station users, click .1568
Reuters Plus users search on RCH/US
For a summary of rating and price target changes on non-S&P 500 companies:
Reuters 3000Xtra users, double-click
Reuters Station users, click .2102
Reuters Plus users search on RCH/US2
For a summary of rating and price target changes on Canadian companies:
Reuters 3000Xtra users, double-click
Reuters Station users, click .4899
Reuters Plus users search on RCH/CA
(Bangalore Equities Newsdesk +91 80 4135 5800; within U.S. +1 646 223 8780)
COPYRIGHT
Copyright Thomson Reuters 2010. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
More News related to YMI
YM BioSciences (YMI) Expands Phase I/II JAK Inhibitor Trial
YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387
YM BioSciences (YMI) Misses Q1 EPS by 2c
YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results
YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS
More News related to YMI
More News related to Corporate News
GM (GM) could be added to Russell 3000 in December, Russell says
Exelixis (EXEL) Announces Interim Data for Ovarian Cancer Treatment with XL-184
Tree.com (TREE) shares resume trading up 9%
Tree.com (TREE) shares set to resume trading at 9:45am ET
FUQI Int'l (FUQI) Receives Letter of Noncompliance from Nasdaq
More News related to Corporate News
November 18, 2010 8:29 AM EST
YM BioSciences Inc. (NYSE Amex: YMI) reported that the Phase I/II clinical trial for its orally available JAK1/JAK2 inhibitor, CYT387, in patients with myelofibrosis has been expanded to five sites. Of the additional sites, the Stanford Cancer Center (Stanford, California) under Principal Investigator Jason Gotlib, MD has already commenced enrolling patients.
YM also announced that the trial protocol has been extended to allow patients who have derived a clinical benefit to continue to receive treatment beyond the nine cycles of the core protocol. Subjects enrolled in the extension protocol will be evaluated every three months for up to 24 cycles of CYT387 treatment.
und wehe die Karre nippelt ab!
DaGrB
;-)
wolle Rose kaufen?
Optionen
| Boardmail an "buran" |
Wertpapier: YM BioSciences |
also Du kannst doch pushen dailytrade,ich weiss das.
(1,84$ fehlen halt noch)
*g*
DaGrB
Ps und nicht versemmeln!
Optionen
| Boardmail an "buran" |
Wertpapier: YM BioSciences |
ym bio macht das schon
asknet auch
keryx auch
....und und und
:-)
schau Dir mal den Chart an,aber nicht erschrecken"entzückend" sieht anders aus
GrB
Optionen
| Boardmail an "buran" |
Wertpapier: YM BioSciences |